Idiopathic brain calcification in a patient with hereditary hemochromatosis

Stefania Scarlini, Francesco Cavallieri, Massimo Fiorini, Elisa Menozzi, Francesca Ferrara, Francesca Cavalleri, Chiara Reale, Barbara Garavaglia, Antonello Pietrangelo, Franco Valzania and Elena Corradini

Abstract

Background: Detection of brain-MRI T2/T2* gradient echo images (T2*GRE)-hypointensity can be compatible with iron accumulation and leads to a differential diagnosis work-up including neurodegeneration with brain iron accumulation (NBIA) and Wilson Disease. Idiopathic or secondary brain calcification can be also associated with neurological involvement and brain-MRI T2/T2*GRE-hypointensity. Hereditary hemochromatosis (HH), characterized by systemic iron loading, usually does not involve the CNS, and only sporadic cases of neurological abnormalities or brain-MRI T2/T2*GRE-hypointensity have been reported.

Case presentation: A 59-year-old man came to our observation after a diagnosis of HH carried out in another hospital 2 years before. First-level genetic test had revealed a homozygous HFE p.Cys282Tyr (C282Y) mutation compatible with the diagnosis of HFE-related HH, thus phlebotomy treatment was started. The patient had a history of metabolic syndrome, type-2 diabetes, autoimmune thyroiditis and severe chondrocalcinosis. Brain-MRI showed the presence of bilateral T2*GRE hypointensities within globus pallidus, substantia nigra, dentate nucleus and left pulvinar that were considered expression of cerebral siderosis. No neurological symptoms or family history of neurological disease were reported. Neurological examination revealed only mild right-sided hypokinetic-rigid syndrome. Vitamin D–PTH axis, measurements of serum ceruloplasmin and copper, and urinary copper were within the normal range. A brain computed tomography (CT) was performed to better characterize the suspected and unexplained brain iron accumulation. On the CT images, the hypointense regions in the brain MRI were hyperdense. DNA sequence analysis of genes associated with primary familial brain calcification and NBIA was negative.

Conclusions: This report highlights the importance of brain CT-scan in ambiguous cases of suspected cerebral siderosis, and suggests that HH patients with a severe phenotype, and likely associated with chondrocalcinosis, may display also brain calcifications. Further studies are needed to confirm this hypothesis. So far, we can speculate that iron and calcium homeostasis could be reciprocally connected within the basal ganglia.

Keywords: Basal ganglia, Brain calcification, Calcium, Hereditary hemochromatosis, Iron
Background
Detection of brain MRI T2/T2* gradient echo images (T2*GRE) hypointensity has an extensive differential diagnosis. The most common causes of these findings are age-related, secondary or idiopathic brain calcifications. The secondary form may be due to endocrine disease with alteration of calcium and phosphate homeostasis (e.g. hypoparathyroidism, pseudo-hypoparathyroidism, hyperparathyroidism), rare brain infections (including tuberculosis and congenital toxoplasmosis), toxin exposure (such as lead and carbon monoxide), neurodegenerative changes (diffuse neurofibrillary tangles with calcification, multiple system atrophy), leukemia, trauma, autoimmune or mitochondrial disease, while the idiopathic form consists of primary familial brain calcification [1, 2]. However, T2/T2*GRE hypointensity can be also compatible with iron accumulation and leads to a differential diagnosis work-up including neurodegeneration with brain iron accumulation (NBIA) and Wilson disease. All these conditions may present with neurological involvement [3].

Hereditary hemochromatosis (HH), a syndrome characterized by systemic iron loading, usually does not involve the central nervous system (CNS), and only sporadic cases of neurological abnormalities or brain-MRI T2/T2*GRE hypointensity have been reported [4]. On the contrary, arthropathy is a common finding in HH patients, and calcification within the cartilage (chondrocalcinosis) can be observed in articular and non-articular sites [5].

Case presentation
A 59-year-old man came to our observation for clinical and therapeutic evaluation after a diagnosis of HH carried out in another hospital 2 years before. Ferritin was reported close to 7000 ng/ml at that time. First-level genetic test had revealed a homozygous HFE p.Cys282Tyr (C282Y) mutation compatible with the diagnosis of HFE-related HH, thus phlebotomy treatment was started. The patient had a history of metabolic syndrome, type-2 diabetes on metformin treatment, autoimmune hypothyroidism on levothyroxine therapy, particularly in cerebellar and pallidal regions. In more detail, the dentate nuclei presented a bilateral hypointensity on T2*GRE and T2-weighted images with only a slightly hyperdense peripheral rim on the CT scan, possibly related to “blooming” of iron deposits. On the contrary, the peridentate white matter is characterized by the absence of T2 or T2*GRE hypointensity but the presence of symmetrical bilateral hyperdensity compatible with calcification. The GP was bilaterally characterized by a central hypointensity with blooming effect on T2*GRE images, possibly related to iron accumulation. Instead, the CT scan showed an hypodense peripheral rim within the lateral part of the external GP and the medial part of the internal GP with a relative sparing of the central portion of the GP.
as in GP and pulvinar, hypointensity was more evident in T2*GRE images than in T2 images. Infectious, traumatic, or mitochondrial diseases, and hypoparathyroidism or pseudo-hypoparathyroidism were excluded on the basis of patient’s medical history and full clinical/biochemical examination, including endocrine tests. Also, the sequencing of primary familial brain calcification-associated genes (SCL20A2, PDGFBR, PDGFRB, XPR1, MYORG) and NBIA genes (PANK2, PLA2G6, WDR45, FTL, C19ORF12, FA2H, COASY, CP, DCAF17, ATP13A2, FTH1, MECR, GLB1, PPCS, PPCDC, REPS1, ATP7B) was negative.

Discussion
HH is defined as a systemic iron overload of genetic origin due to lack of synthesis or activity of hepcidin, the hormone that regulates the iron entry into the bloodstream, leading to excess circulating iron, tissue iron deposition and organ disease affecting liver, heart, endocrine glands, joints and skin. Although mutations in five different genes have been linked to the development of HH, most cases are due to the homozygous C282Y amino acid substitution in the HFE protein [6]. The main hepatic manifestations are hepatomegaly and progressive liver disease, characterized by fibrogenesis and cancer risk. Moreover, in patients with early and massive iron overload, iron-induced toxicity can lead to cardiac contractile dysfunction (first diastolic and then also systolic) and electrical disturbances (mainly bradyarrhythmia, heart block or atrial fibrillation). HH related endocrinopathies include diabetes mellitus and, more rarely, hypopituitarism, adrenal insufficiency and hypothyroidism, whereas melanoderma (darkening of the skin) is the leading dermatological sign. Joint pain is frequent in HH patients and is often due to
chondrocalcinosis or mono/oligo/polyarthritis, typically in the second and third metacarphopalangeal joints and ankles [6]. Usually HH does not involve the central nervous system (CNS), and only sporadic descriptions (i.e. case reports and small case series) of neurological abnormalities have been reported [4, 7, 8]. Different presentations include both neuroimaging findings suggestive of iron deposition in the absence of neurological manifestations, and neurological symptoms/signs in patients with normal MRI scan. Furthermore, a few cases of basal ganglia calcifications have been described [4, 8]. Interestingly, variable or absent responses to iron depletion are reported in these patients. The basal ganglia, in particular the putamen and GP, may represent a preferential niche for this homeostatic derangement based on their documented tendency to iron deposition and their major susceptibility to metabolic alterations due to rich vascular supply and high metabolic activity with increased utilization of glucose and oxygen [9].

Neuroimaging plays a crucial role in distinguishing NBIA (particularly PKAN) from syndrome of brain calcification. Importantly, since brain calcifications appear in MRI with various signal intensities, including T2*GRE-hypointensity that is also a typical feature of brain iron accumulation, CT-scan is considered the gold standard in their detection [3, 10]. In the present case, a missed diagnosis of cerebral calcifications was avoided through the use of CT of the brain. Notably, the prevalence of calcifications and their relationship to T2 or T2*GRE hypointensity in brain accumulation disorders is not well understood because of an underrepresentation of CT data in literature. Moreover, MRI is often the first and only imaging study for assessment of either iron accumulation or movement disorders in clinical practice.

Based on the negative results of genetic and laboratory tests, the etiology of brain calcifications remains elusive in our patient. However, considering the severe HH phenotype (including massive hepatic iron deposition, advanced liver disease, mild heart iron overload, multiple endocrinopathies likely promoted or enhanced by iron toxicity, and chondrocalcinosis), it could be hypothesized that a local alteration of phosphate and calcium metabolism related to HH has led to calcium deposition in the basal ganglia. This hypothesis is based on previous in vitro studies where McCarty and colleagues demonstrate in red cells and synovial fluid that iron, as Fe2+ ion, inhibits pyrophosphatase, leading to a diminished hydrolyse of inorganic pyrophosphate with a consequent precipitation of inorganic pyrophosphate with calcium [11]. This mechanism, which is probably the pathophysiological process underlying chondrocalcinosis in HH, could also be a possible cause of the brain calcifications described in the present case. To further support our hypothesis, the slight morphological discrepancy between MRI and CT signal patterns in cerebellar and pallidal regions could suggest that the MRI hypointensity may be related to accumulation of both iron and calcium. Interestingly, CT hyperdense lesions within basal ganglia have been previously reported in HH patients, [4, 7, 8, 12] while more recently it has been described that patients with NBIA syndromes may present basal ganglia calcifications, [10] suggesting a close link between iron and calcium metabolism within the CNS. In our case, the calcification pattern is greater than and different from the calcification patterns seen in physiologic calcifications and in the few published cases of calcifications with HH, which appear more similar to physiologic calcifications [7, 12]. Furthermore, the additional areas of calcification appear to correspond to previously described areas of brain signal abnormality in HH summarized in Kumar et al. [4].

In addition to the standard T2*GRE sequence, susceptibility weighted imaging could provide a more sensitive evaluation of T2*GRE hypointensity and the “blooming” that results from magnetic field inhomogeneity, including from paramagnetic materials. Also, this imaging technique has some ability to differentiate different T2*GRE hypointense calcium from iron because of different paramagnetic properties [13–15]. Unfortunately, susceptibility weighted imaging was not available in our case thus limiting the differentiation of iron and calcium brain deposits. An understandable lack of pathology confirmation of iron and calcium is a known minor limitation in terms of interpreting findings. While not pathologically proven, the CT hyperattenuation in this case is most consistent with calcification, as previously reported in common clinical practice and in the literature [3, 10]. It is difficult to find CT-pathologic correlation in the literature for HH and brain iron accumulation, which may in part be because some or most brain iron accumulation do not demonstrate calcification [12, 16].

In conclusion, this report highlights the importance of brain CT-scan in ambiguous cases of suspected cerebral siderosis, and suggests that HH patients with severe full-blown phenotype, likely associated with chondrocalcinosis, may display also brain calcifications. More work is needed to characterize the prevalence of brain calcifications in HH and how it may be related to disease diagnosis, staging, prognosis and management. So far, we can speculate that iron and calcium homeostasis could be reciprocally connected within the basal ganglia and/or cerebellum. Further studies are needed to confirm and clarify our hypothesis. On this basis, although CNS involvement is rarely described in HH patients, in presence of neurological symptoms and/or brain- MRI T2*GRE-hypointensities we recommend to always consider a CT scan not only to clarify the nature of brain deposits but also to verify if both iron and calcium are present.
Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ATP1A3:ATPase cation transporting 1A3; ATP7B: ATPase copper transporting beta; BMI: Body mass index; CBC: Complete blood count; C19orf12: Chromosome 19 open reading frame 12; COASY: Coenzyme A synthase; CP: Ceruloplasmin; CT: Computed tomography; DCAF17, DDB1 and CUL4 associated factor 17; FAZ2: Fatty acid 2-hydroxylase; FTH1: Ferritin heavy chain 1; FTL: Ferritin light chain; GLB1: Galactosidase beta 1; GP: Globus Pallidus; HAMP: Hepcidin gene; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HFE: Hemochromatosis gene; HH: Hereditary haemochromatosis; HJV: Hemojuvelin gene; LDH: Lactate dehydrogenase; MECR: Mitochondrial trans-2-enoyl-CoA reductase; MRI: Magnetic resonance imaging; MYORG: Myogenesising-regulating glycosidase; NBI: Neurodegeneration with brain iron accumulation; PANK2: Pantothenate kinase 2; PDGFB: Platelet-derived growth factor beta chain; PDGFRB: Platelet-derived growth factor receptor beta; PLA2G6: Phospholipase A2 group VI; PPDCD: Phosphopantothenoylcysteine decarboxylase; PPCS: Phosphopantothenoylcysteine synthetase; PTH: Parathyroid hormone; REP51: RALBP1 associated Eps domain containing 1; SLC40A1: Solute carrier 40 member 1; TFR2: Transferrin receptor 2; T2*GRE: T2* gradient echo images; WDR45: WD repeat domain 45; XPR1: Xenotropic and polytopic retrovirus receptor 1

Acknowledgements
We thank the patient for giving consent to the publication. We are grateful to the reviewer, Dr. Atul K. Mallick, for his valuable suggestions.

Authors’ contributions
SS analyzed and interpreted the patient clinical data related to HH and drafted the article. FC analyzed and interpreted the patient data regarding neurological signs and symptoms and drafted the article. MF analyzed and interpreted the patient clinical data related to HH and drafted the article. EM analyzed and interpreted the patient data regarding neurological signs and symptoms. FF performed genetic analysis. CR performed Brain-MRI and CT scan and revised the manuscript critically for important intellectual content. FC performed Brain-MRI and CT scan and revised the manuscript critically for important intellectual content. FA2H: Fatty acid 2-hydroxylase; FTH1: Ferritin heavy chain 1; FTL: Ferritin light chain; GLB1: Galactosidase beta 1; GP: Globus Pallidus; HAMP: Hepcidin gene; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HFE: Hemochromatosis gene; HH: Hereditary haemochromatosis; HJV: Hemojuvelin gene; LDH: Lactate dehydrogenase; MECR: Mitochondrial trans-2-enoyl-CoA reductase; MRI: Magnetic resonance imaging; MYORG: Myogenesising-regulating glycosidase; NBI: Neurodegeneration with brain iron accumulation; PANK2: Pantothenate kinase 2; PDGFB: Platelet-derived growth factor beta chain; PDGFRB: Platelet-derived growth factor receptor beta; PLA2G6: Phospholipase A2 group VI; PPDCD: Phosphopantothenoylcysteine decarboxylase; PPCS: Phosphopantothenoylcysteine synthetase; PTH: Parathyroid hormone; REP51: RALBP1 associated Eps domain containing 1; SLC40A1: Solute carrier 40 member 1; TFR2: Transferrin receptor 2; T2*GRE: T2* gradient echo images; WDR45: WD repeat domain 45; XPR1: Xenotropic and polytopic retrovirus receptor 1

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Competing interests
Stefania Scarlini reports no disclosures. Francesco Cavallieri reports no disclosures. Massimo Fiorini reports no disclosures. Elisa Menozzi reports no disclosures. Francesca Ferrara reports no disclosures. Francesca Cavallieri reports no disclosures. Chiara Reale reports no disclosures. Barbara Garavaglia reports no disclosures. Antonello Pietrangelo reports no disclosures. Franco Valzania reports no disclosures.

Elena Corradini reports no disclosures.

Author details
1 Internal Medicine Unit and Centre for Hemochromatosis and Heredometabolic Liver Diseases, EuroBloodNet Referential Center for Iron Disorders, Policlinico, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. 2 Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy. 3 Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. 4 Department of Neuroscience, S. Agostino-Esteense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. 5 Department of Neuroradiology, Policlinico, Azienda Ospedaliero Universitaria di Modena, Modena, Italy. 6 Medical Genetics and Neurogenetics Unit, Movement Disorders Diagnostic Section, Fondazione IRCCS Istituto Neurologico “C. Besta”, Milan, Italy. 7 Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Received: 23 July 2019 Accepted: 17 March 2020
Published online: 30 March 2020

References
1. Bonazza S, La Morgia C, Martinelli P, Capellari S. Strio-pallido-dentate calcinosis: a diagnostic approach in adult patients. Neurol Sci. 2011;32:537–45.
2. Batia A, Tai YY, Schottlaender L, Erro R, Balint B, Bhatia KP. Deconstructing Fahr’s disease/syndrome of brain calcification in the era of new genes. Parkinsonism Relat Disord. 2017;37:1–10.
3. Krueer MC, Boddart N, Schneider SA, Houlden H, Bhatia KP, Gregory A, Anderson JC, Rooney WD, Hogarth P, Hayflick SJ. Neuroimaging features of neurodegeneration with brain iron accumulation. AINR Am J Neuroradiol. 2012;33:407–14.
4. Kumar N, Rzek P, Sadikovic B, Adams PC, Jog M. Movement disorders associated with hemochromatosis. Can J Neurol Sci. 2016;43:801–8.
5. van Vulpen LF, Roosendaal G, van Asbeck BS, Mastbergen SC, Lafeber FP, Schutgens RE. The detrimental effects of iron on the joint: a comparison between haemochromatosis and haemophilia. J Clin Pathol. 2015;68:592–600.
6. Brissot P, Pietrangeli A, Adams P, De Graaff B, McLarens CE, Loréal O. Haemochromatosis. Nat Rev Dis Primers. 2018;4:18016.
7. Berg D, Hogenmuller U, Hofmann E, Fischer R, Krous M, Scheufler M, Becker G. The basal ganglia in haemochromatosis. Neuroendocrinology. 2000;42:9–13.
8. Scale T, Lewis C, Hedayat AB, Wani M. Cerebral calcification from Fahr’s disease with co-existing haemochromatosis. Prog Neurol Psychiatry. 2014;18(6):1–6.
9. Hegde AN, Mohan S, Lath N, Lim CCT. Differential diagnosis for bilateral abnormalities of the basal ganglia and thalamus. Radiographics. 2011;31:315–30.
10. Fasano A, Shahidi G, Lang AE, Rohani M. Basal ganglia calcification in a case of PKAN. Parkinsonism Relat Disord. 2017;36:98–9.
11. McCarty DJ, Pepe PF. Erythrocyte neutral inorganic pyrophosphatase in pseudogout. J Lab Clin Med. 1972;79:277–84.
12. Jones HR Jr, Hedley-Whyte ET. Idiopathic hemochromatosis (HH) in adults: a diagnostic approach in adult patients. Neurol Sci. 2011;32:537–45.
13. Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol. 2009;30:232–52.
14. Barbosa JHO, Santos AC, Salomao CEG. Susceptibility weighted imaging: differentiating between calcification and hemosiderin. Radiol Bras. 2015;45:229–36.
15. Li C, Imbesi S, Lee R, Haacke E, Chen J. Potential pitfalls when differentiating hemorrhage and calcium on susceptibility-weighted images. Neurographics. 2016;6:123–6.
16. Botsford E, George J, Buckley EE. Parkinson’s disease and metal storage disorders: a systematic review. Brain Sci. 2016;8:194.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.